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Abstract  
Takayasu arteritis (TA) and inflammatory bowel disease (IBD) are chronic inflammatory 
disorders. The mechanisms underlying these diseases are not precisely known, but tumor 
necrosis factor alpha (TNF-α) is considered to have an important role in the pathophysiology of 
both TA and IBD. Simultaneous occurrence of both TA and IBD is rare. Our first case was a 
42-year-old woman with TA and inflammatory bowel disease unclassified. The patient was 
refractory to treatment with an immunomodulator, and infliximab (IFX) was started. After 
starting IFX, clinical remission was achieved and maintained for 2 years. The second case was a 
34-year-old woman with TA accompanied by Crohn’s disease. Because her abdominal symptoms 
relapsed despite treatment with an immunomodulator, IFX was started. Both diseases were well 
controlled for 2 years by scheduled maintenance therapy with IFX. Relapse of the TA required 
increased doses of IFX at shorter intervals, which relieved her symptoms. 
From literature we identified and our cases, there were nine cases for which IFX was effective. 
They may demonstrate the efficacy of IFX for IBD with TA and emphasize the role of TNF-α in 
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Introduction 
Takayasu arteritis (TA) is a chronic inflammatory vasculitis of unknown etiology that affects the 
large vessels, predominantly the aorta and its main branches. Vessel inflammation leads to wall 
thickening, fibrosis, stenosis, and thrombosis formation. Various ischemic symptoms appear 
depending on the affected arteries, such as chest, limb, and abdominal pain [1, 2]. 
Although TA has been associated with other autoimmune diseases, such as glomerulonephritis, 
systemic lupus erythematosus, juvenile idiopathic arthritis, anterior uveitis, sarcoidosis, and 
Sweet’s syndromes, the coexistence of TA and inflammatory bowel disease (IBD) is rare [1-3]. 
The pathogenesis of both TA and IBD remains unclear. A common pathomechanism between the 
two diseases, however, is conceivable, because treatment with anti-tumor necrosis factor alpha 
(TNF-α) antibody often leads to a favorable clinical outcome of TA and IBD [4-7]. 
Several case reports have demonstrated the therapeutic effects of anti-TNF-α antibody in IBD 
with TA [6-10]. We herein report our two cases of IBD with TA successfully treated with 
infliximab (IFX) and discuss previously published reports of the efficacy and safety of IFX 
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Case Report 
Case 1 
 A 42-year-old woman suffering from TA with severe arterial stenosis was followed as an 
outpatient at the Department of Cardiovascular Medicine, Kyoto University Hospital. In April 
2007, she complained of recurrent abdominal pain with hematochezia. Colonoscopic findings 
revealed multiple ulcerations from the ileocecal region to the ascending colon. 
Contrast-enhanced computed tomography revealed stenosis of the superior mesenteric artery root. 
We considered that her abdominal symptoms were due to ischemia of the superior mesenteric 
artery. Percutaneous transcatheter angioplasty of the superior mesenteric artery was performed 
but did not relieve her symptoms. Colonoscopic findings after percutaneous transcatheter 
angioplasty revealed no significant change. Although her colonoscopic findings mimicked 
ulcerative colitis (UC), the involved areas were inconsistent with UC (Fig. 1). Histological 
findings of biopsy specimens from colonic mucosa revealed chronic inflammatory features with 
no characteristic features of UC and Crohn’s disease (CD). Fecal culture was negative for 
pathogenic microbes. Intranuclear inclusion body of cytomegalovirus was not detected in biopsy 
specimens. Contrast-enhanced computed tomography did not reveal any abnormality of her small 
intestine. Therefore, she was diagnosed with inflammatory bowel disease unclassified (IBDU) 
accompanied by TA. Administration of prednisolone (PSL) and mercaptopurine did not 
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ameliorate her symptoms, and therefore IFX treatment was initiated. Following treatment with 
IFX, her abdominal symptoms subsided and clinical remission of her IBD was maintained by 
scheduled maintenance therapy with IFX. She was successfully tapered off the PSL and 
contrast-enhanced computed tomography revealed no new vascular lesions. 
 
Case 2 
 A 34-year-old woman presented with anterior neck pain. Physical examination showed bruit of 
left carotid artery on auscultation. Contrast-enhanced computed tomography revealed stenoses of 
left carotid artery, aortic arch, celiac artery and superior mesenteric artery. These clinical and 
imaging findings met the criteria of TA described in the Japanese Circulation Society guideline. 
Therefore, she was diagnosed with TA and treated with oral administration of PSL. She 
complained of worsening diarrhea and body weight loss under the treatment with PSL 10 mg/day. 
Colonoscopy revealed multiple ulcerations at the terminal ileum. Histologic findings of biopsy 
specimens obtained from the ulcerative lesions indicated noncaseating granuloma and led to a 
diagnosis of CD. She was started on 2250 mg/day mesalazine and 50 mg/day azathioprine 
(AZA) with continued PSL at 10 mg/day. Although her abdominal symptoms subsided for 7 
months after combined treatment with mesalazine and AZA, her symptoms recurred. 
Double-balloon enteroscopy revealed discontinuous longitudinal ulcers from the distal ileum to 
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the ileocecal valve (Fig. 2). Because her CD disease activity was not controlled with 
conventional therapies, treatment with IFX was initiated. After starting 5 mg/kg of IFX, clinical 
remission of her CD was rapidly achieved and treatment with PSL could be tapered off 
completely. Although she exhibited no symptoms related to CD by a scheduled maintenance 
therapy with IFX for 2 years, laboratory data revealed gradually increasing serum C-reactive 
protein (CRP) levels. The uptake of fluorodeoxyglucose in the thoracic aorta wall in positron 
emission tomography suggested that the increased serum CRP levels were associated with TA 
activity (Fig. 3a). The dose of IFX was increased (from 5 mg/kg to 10 mg/kg) and the dosing 
interval was shortened (from every 8 weeks to every 6 weeks) to normalize the CRP levels. The 
uptake of fluorodeoxyglucose in the thoracic aorta wall in positron emission tomography 
disappeared and double-balloon enteroscopy revealed the disappearance of multiple ulcerations 
in the distal ileum (Fig. 3b).  
 
Characteristics and outcomes of the 9 patients with IBD and TA treated with anti-TNF-α 
agents 
Including our 2 cases, there have been a total of 9 cases (8 women, 1 man) with IBD and TA 
successfully treated with anti-TNF-α agents (Table 1). There were seven cases with CD, one case 
with UC, and one case with IBDU. IBD preceded TA in 4 of the 9 cases and TA preceded IBD in 
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our 2 cases. In the remaining 3 cases, IBD and TA were simultaneously diagnosed. Mean age at 
definitive diagnosis of both IBD and TA was 28 years (median 28 years, range 16-49 years). PSL 
was administered in all 9 cases and immunomodulators such as AZA, 6-mercaptopurine, and 
methotrexate were administered in 7 cases before treatment with IFX was initiated. In 8 of 9 
cases, the clinical symptoms subsided following the administration of IFX and scheduled 
maintenance therapy with IFX. In the remaining 1 case, IFX was switched to adalimumab 
(ADA) because of an allergic reaction to IFX and the patient’s clinical symptoms disappeared 
after switching to ADA. In 5 of 9 cases, PSL was completely tapered after treatment with the 
anti-TNF-α was initiated. 
 
Discussion 
Based on the clinical outcome of our 2 cases, IFX was effective for achieving clinical remission 
of IBD concomitant with TA. Additionally, IFX treatment inhibited the progression of TA. These 
findings indicate the possibility that TNF-α is mainly involved in the pathophysiology of IBD 
concomitant with TA. 
The simultaneous occurrence of IBD and TA is considered rare [3, 8]. Reports on IBD 
concomitant with TA have increased recently, however, although the reason for this is unclear [3, 
7-13]. Until now, there have been 56 IBD cases concomitant with TA including our two cases, 
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and the majority of cases were treated with corticosteroid therapy [3, 6-13]. 
Treatment with corticosteroids is effective for patients with both IBD and TA, but long-term use 
of corticosteroids is not necessarily favorable because of the related side effects [1, 2, 14]. 
Therefore, treatment with immunomodulators is usually started to control inflammation from 
both diseases as well as other autoimmune diseases. Administration of anti-TNF-α antibody has 
been considered in recent cases that failed to respond to conventional treatment, including 
immunomodulators [5-7]. 
IFX treatment was administered in only a total of 9 of 56 cases, including our 2 cases [6-10]. 
Only one case required switching from IFX to ADA due to an allergic reaction related to IFX. In 
all cases, the symptoms of both IBD and TA were ameliorated by treatment with IFX or ADA. 
These data suggest that anti-TNF-α treatment for IBD concomitant with TA might lead to a 
clinically favorable outcome compared with other inflammatory diseases. In fact, in our case 2 
presented here, exacerbated inflammation of TA during scheduled maintenance therapy with IFX 
was reduced by increasing the dose and administration interval of IFX. Notably, PSL could be 
completely tapered off in 5 of 9 cases after starting anti-TNF-α treatment. 
HLA analysis revealed that HLA-B52 and DR2 are common genetic factors that predispose to 
TA and UC [13]. In contrast, there is no clear association between a common HLA genotype 
shared by both CD and TA, although both diseases are granulomatous in nature with an integral 
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cell-mediated autoimmune component in the pathogenesis of these two diseases [3, 15]. Both 
IBD and TA share common features of autoimmune origin. In addition, TNF-α is thought to 
induce mucosal inflammation in IBD patients and the granulomatous process in the vessel walls 
of patients with TA. It is therefore likely that treatment with anti-TNF-α agents will be useful in 
abrogating the immunoinflammatory features of coexisting TA and IBD. 
On the other hand, there are some reports of patients with IBD developing TA despite IFX 
treatment [11, 12]. Because a subpopulation of patients with IBD also has TA subclinically, it is 
not surprising that TA would appear during treatment for IBD. The mechanism underlying the 
appearance of TA in IBD patients treated with anti-TNF-α agents, however, is unclear. In 
addition, because the present study is limited in that previous cases report a short-term follow-up, 
we cannot comment on the long-term efficacy and safety of IFX treatment, especially when it is 
necessary to increase the dose and administration interval. 
In conclusion, this review of previous cases reports and our cases may demonstrate the efficacy 
of anti-TNF-α treatment for patients with coexisting IBD and TA, and provide support for 
treatment with anti-TNF-α agents in cases refractory to conventional therapies. Further 
follow-up studies with a greater number of patients are required to assess the long-term efficacy 
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Figure legends 
Figure 1 
Colonoscopy image showing mimicked UC, including friability of mucosa with 
erythema and ulcerations from the terminal ileum to the ascending colon. 
 
Figure 2 




a. Positron emission tomography image showing the uptake of fluorodeoxyglucose 
in the thoracic aorta wall. (arrow) 
b. Positron emission tomography image showing the disappearance of 
fluorodeoxyglucose in the thoracic aorta wall. (left panel)  
Double-balloon enteroscopy image showing the disappearance of multiple 
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Table 
Table 1  9 cases reports of IBD with TA treated successfully by IFX. 
 
IBDU: inflammatory bowel disease unclassified, PSL: prednisolone, AZA: azathioprine,  
6-MP: 6-mercaptopurine, MTX: methotrexate, IFX: infliximab,  






Kellermayer 2008 F 12 (CD) 17 PSL, 5-ASA, 6-MP, IFX discontinuation 8 
Judah 2009 F 24 (CD) 24 PSL, IFX discontinuation 9 
F 30 (CD) 49 PSL, antibiotics, 6-MP, IFX unknown 
F 30 (CD) 30 PSL, AZA, IFX, ADA discontinuation 
Calderon 2010 F 17 (CD) 20 PSL, 5-ASA, MTX, AZA, IFX unknown 6 
Ratuapli 2010 M 16 (CD) 16 PSL, MTX, AZA, IFX discontinuation 10 
Gecse 2011 F 20 (UC) 30 PSL, sulfasalazine, IFX unknown 7 
Our case 2012 F 37 (IBDU) 31 PSL, 6-MP, IFX discontinuation 
F 28 (CD) 22 PSL, 5-ASA, AZA, IFX continuation 
Reference Author Age at diagnosis. PSL Therapy Year Gender 
